Details for Patent: 7,144,884

✉ Email this page to a colleague

Which drugs does patent 7,144,884 protect, and when does it expire?

Patent 7,144,884 protects TRINTELLIX and is included in one NDA.

Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-nine patent family members in thirty-six countries.

Summary for Patent: 7,144,884

Title:	Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Abstract:	The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001##
Inventor(s):	Ruhland; Thomas (Roskilde, DK), Smith; Garrick Paul (Valby, DK), Bang-Andersen; Benny (Copenhagen, DK), Puschl; Ask (Frederiksberg, DK), Moltzen; Ejner Knud (Gentofte, DK), Andersen; Kim (Ridgewood, NJ)
Assignee:	H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:	10/488,280
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,144,884
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,144,884

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial			Y		⤷ Try a Trial
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-002	Sep 30, 2013		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial			Y		⤷ Try a Trial
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial			Y		⤷ Try a Trial
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial			Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,144,884

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2001 01466	Oct 04, 2001

PCT Information
PCT Filed	October 02, 2002	PCT Application Number:	PCT/DK02/00659
PCT Publication Date:	April 10, 2003	PCT Publication Number:	WO03/029232

International Family Members for US Patent 7,144,884

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036659	⤷ Try a Trial
Argentina	066460	⤷ Try a Trial
Austria	386730	⤷ Try a Trial
Austria	441631	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,144,884

Foreign Priority and PCT Information for Patent: 7,144,884

Make Better Decisions: Try a trial or see plans & pricing